ArticleScientific reports2025
Glucocorticoid inhibits lung cancer cells proliferation and migration by suppressing smad2/3 activation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glucocorticoid (GCs), as an adjuvant drug, is widely used for alleviating chemotherapy or immunotherapy-induced adverse events, such as nausea and immune-related diseases in lung cancer treatment. However, whether GCs directly affects lung cancer progression remains unclear. This study focused on the effects of dexamethasone (DEX) on the proliferation and migration of lung cancer cells as well as the related potential mechanisms using EdU, CCK8, Transwell, Wound healing, TCGA database, HPA database, qPCR and Western blotting. Additionally, subcutaneous tumor and tail vein tumor injection models were established for investigating DEX action in vivo. Further, to confirm the key functional of Smad2/3 for DEX regulating lung cancer cells proliferation and migration. Mechanistic assays explored the upstream regulatory molecules TGFβ1, TGFβR1 and p-TGFβR1 expression after DEX treatment. Moreover, DEX modulates lung cancer cell proliferation and migration on a glucocorticoid receptor (GR)-independent manner and the association with Smad2/3 activation were investigated. Results: The results showed that DEX (1 µM) treatment significantly inhibited the proliferation and the migration of lung cancer cells A549 and LLC cells. TCGA and HPA databases showed Smad2/3 expression was positively correlated with lung cancer progression. Mechanistically, DEX treatment significantly inhibited Smad2/3 activation in vitro and in vivo, manifested as a decrease in the expression of p-Smad2 (Ser465/467), Smad2, p-Smad3 (Ser423/425), and Smad3. Smad2/3 knockdown significantly inhibit the proliferation, migration and Smad2/3 activity of A549 and LLC cells. Creatine, the agonist of Smad2/3 activation, markedly reversed the inhibitory effects of DEX on the proliferation and migration of A549 and LLC cells. Smad2/3 overexpression also reversed the inhibitory effects of DEX on A549 cell proliferation and migration. Further studies showed DEX inhibited the expression of TGFβR1 and p-TGFβR1(Ser165) and the levels of TGFβ1. Moreover, GR knockout significantly promoted the proliferation, migration and Smad2/3 activity in A549 cell. DEX can inhibits A549 cell proliferation and migration through suppressing Smad2/3 activation independent of GR. Conclusion: DEX inhibited the proliferation and migration of lung cancer cells by suppressing Smad2/3 activation, providing a theoretical basis and experimental data for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.